Bevacizumab (Avastatin)
Epidemiology, molecular biology, diagnostic and therapeutic strategy of malignant pleural mesothelioma in 2007 – an update
Revue des Maladies Respiratoires. 2007 Oct;24(8 Pt 2):6S157-64. [Link] Porret E, Madelaine J, Galateau-Sallé F, Bergot E, Zalcman G. Service de Pneumologie, Pôle Coeur-Poumons-Vaisseaux, Université Basse-Normandie, CHU de Caen, France. Abstract Malignant pleural mesothelioma (MPM) is a rare tumour due to occupational asbestos exposure. The incidence of MPM will continue to increase until 2020-2030. The…
Read MoreThe Therapeutic Efficacy of Anti–Vascular Endothelial Growth Factor Antibody, Bevacizumab, and Pemetrexed against Orthotopically Implanted Human Pleural Mesothelioma Cells in Severe Combined Immunodeficient Mice
Clinical Cancer Research. 13, 5918-5925, October 1, 2007. [Link] Li Q, Yano S, Ogino H, Wang W, Uehara H, Nishioka Y, Sone S. Department of Internal Medicine and Molecular Therapeutics, The University of Tokushima Graduate School, Tokushima, Japan Abstract Purpose: Malignant pleural mesothelioma (MPM) is an aggressive malignancy, which has a poor prognosis with a…
Read More